SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Dishman Carbogen’s Bavla facility

29 Oct 2018 Evaluate

The US Food and Drug Administration (USFDA) has successfully completed the inspection at Dishman Carbogen Amcis’ Bavla facility on October 26, 2018. The inspection was concluded without any major or critical observations.

Thus, the company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

168.60 -2.00 (-1.17%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×